Intensity Therapeutics Reports $3.3 Million Net Loss in Q1 2025, Highlights Funding Challenges

Intensity Therapeutics, Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $3.3 million, a decrease from the $4.6 million loss recorded in the same period of 2024. The company’s total operating expenses for the quarter were $3.4 million, down from $4.7 million year-over-year, primarily due to reduced research and development costs, which fell by 22% to $2.2 million. General and administrative expenses also decreased by 38% to $1.2 million, reflecting cost-saving measures and a lack of new equity grants during the quarter.

As of March 31, 2025, Intensity Therapeutics had cash and cash equivalents of $0.9 million, a significant decline from $2.6 million at the end of 2024. The company’s total assets decreased to $3.1 million from $4.8 million, while total liabilities rose to $2.7 million, up from $1.9 million. The increase in liabilities was driven by higher accounts payable and accrued expenses, which totaled $1.6 million and $1.0 million, respectively. The accumulated deficit reached $70.1 million, reflecting the ongoing financial challenges faced by the company as it continues to invest in its clinical programs.

In terms of operational developments, Intensity Therapeutics is advancing its lead product candidate, INT230-6, through various clinical trials. The company initiated a Phase 3 trial (INVINCIBLE-3 Study) for soft tissue sarcoma in July 2024, which has enrolled 23 patients before a pause in new site activations due to funding constraints. Additionally, a Phase 2 study (INVINCIBLE-4 Study) in collaboration with the Swiss Group for Clinical Cancer Research was launched in October 2024, targeting localized triple-negative breast cancer. The company is prioritizing funding for this study while continuing to treat patients already enrolled in the INVINCIBLE-3 Study.

Looking ahead, Intensity Therapeutics has expressed concerns regarding its ability to continue as a going concern, emphasizing the need for additional funding to support its operations and clinical trials. The company recently completed a public offering in April 2025, raising approximately $2.35 million in gross proceeds, which it expects will provide sufficient cash to fund operations into the third quarter of 2025. However, the company acknowledges that it may need to pursue further equity or debt financing to sustain its development efforts and achieve profitability in the future.